MAP3K7 and prostate cancer: Our work extends earlier findings that suggest that the effect of MAP3K7 deletions on the prognosis of malignancies is highly dependent on the cell of origin: MAP3K7 deletions are associated with advanced high-risk disease in prostate cancer [16, 27], but with a good prognosis in esophageal squamous cell carcinoma [49].